drugset / Trial / NCT05137171
AK105 Combined With Anlotinib in Patients With Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of AK105 (anti-PD-1 mab) combined with Anlotinib Hydrochloride in the treatment of persistent, recurrent and metastatic cervical cancer.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2024-03-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |